Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Avalon GloboCare Corp. (AVCO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0100+0.0203 (+2.05%)
At close: 4:00PM EDT
1.0100 0.00 (0.00%)
After hours: 05:33PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.9897
Open0.9601
Bid0.9851 x 1100
Ask1.0100 x 1400
Day's Range0.9301 - 1.0300
52 Week Range0.8030 - 1.6500
Volume324,819
Avg. Volume195,387
Market Cap86.26M
Beta (5Y Monthly)0.46
PE Ratio (TTM)N/A
EPS (TTM)-0.1340
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AVCO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Avalon GloboCare Corp.
    Analyst Report: Danaher CorporationIn 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE’s Biopharma business, now called Cytiva, which added to its life sciences segment.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
Advertisement
Advertisement